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1. INTRODUCTION 
1.1 Diffuse midline glioma 
Diffuse midline gliomas (MLGs) are infiltrative gliomas, mainly with an astrocytic 
differentiation, which affect midline structures of central nervous system (CNS): 
cerebellum, ventricles, thalamus, hypothalamus, pineal region, pons, spinal cord and 
brainstem1. MLGs occur more frequently in paediatric patients and young adults, while 
in adults fewer than 10% of diffuse gliomas arise in midline structures.  
MLG typically harbour a missense mutation, p.Lys27Met, in H3 histone family member 
3A (H3F3A) and histone cluster 1 H3 family member B (HIST1H3B) genes. H3F3A 
(1q42.12) and HIST1H3B (6p22.2) genes encode variants of the histone H3 protein, 
which is responsible for chromatin structure and consequently for gene expression. 
While HIST1H3B mutations are anatomically restricted to brainstem2,3, H3F3A mutants 
have been reported in MLG of various locations2,4-9, and other histone variants (e.g. 
H3F3A p.Gly34Val) occur in a subset of hemispheric supratentorial pediatric high-
grade gliomas2,3,8,10. In pediatric MLGs, mutations in histone H3 variants associate with 
more aggressive clinical phenotype and poorer prognosis6,8,11. Based on these 
observations, histone H3-mutant gliomas progressively emerged as a phenotypically 
and molecularly separated group of tumours. The WHO 2016 classification 
subsequently introduced “diffuse midline glioma, H3K27M-mutant” as a new grade IV 
entity, even in the absence of histopathological markers of anaplasia (i.e. mitotic 
figures, microvascular proliferation and necrosis)12. 
Histone protein mutations contribute to gliomagenesis in this subgroup of tumours. 
Histone proteins are modified by the polycomb repressive complex 2 (PRC2) 
methyltransferase and by lysine (K)-specific demethylase (KDM). PRC2 increases 
methylation of Lys27, which promotes a more compact and transcriptionally 
repressed chromatin state. Whereas, KDM demethylase complex removes methyl 
groups from Lys27, promoting an open and transcriptionally active chromatin state. 
Histone H3K27M mutant protein binds PRC2 histone methyltransferase and 
functionally inactivates it, leading to a global reduction of Lys27 methylation, thereby 
promoting an open chromatin structure that favours a deregulated gene 
transcription13 (Figure 1). Nowadays, an inhibitor (GSKJ4) of a protein composing KDM 
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demethylase complex is under study; this molecule is able to increases Lys27 
methylation and so it suppresses gene expression and reduces tumour growth14. 
 
Figure 1. Histone modifications by PRC2 methyltransferase and KDM demethylase activities, and 
associations with transcriptionally active versus inactive states13. 
 
According to a 2016 WHO classification update15, the term “diffuse midline glioma, H3 
K27M-mutant” should be reserved for tumours that are diffuse (infiltrating), midline 
(thalamus, brain stem, spinal cord, etc.), gliomas and harbouring H3K27M mutation; 
it is important to remark that not each CNS tumour that harbours H3K27M mutation 
is a diffuse midline glioma.  Histologically, MLG can resemble astrocytic (30% of all 
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MLGs), oligodendrocytic or other CNS tumours. In the past was known that H3K27M 
mutation was exclusively of MLG, nowadays, there are a number of tumours that are 
not diffuse midline gliomas which reported the same H3K27M mutation, including 
ependymomas, pilocytic astrocytomas, pediatric diffuse astrocytomas and 
gangliogliomas15. Authors showed that there is a group of gliomas that displays high-
grade histology and clinical features and imaging of diffuse midline gliomas but do not 
harbours H3K27M mutation; it has been proposed to introduce H3K27M-wild-type 
tumour entity into WHO classification of CNS tumours2.  
In paediatric patients, MLGs have a more aggressive clinical phenotype and poorer 
prognosis, which is not associated with H3K27M mutation but probably with the age 
of onset. Indeed, studies confirm that there is no association between this mutation 
and a worst overall survival (OS) at any age. The poor prognosis is also due to the 
difficult access to tumour site for surgery16. 
While few studies specifically investigated the molecular landscape of adult MLG, 
recent works suggested that this subset of tumours may present with phenotypic and 
molecular characteristics differing from both pediatric MLG and adult supratentorial 
gliomas. As an illustration, although H3F3A mutations have been reported in adult 
MLG of the thalamus, hypothalamus, pineal region, brainstem, cerebellum and spinal 
cord7,14,17-20, their prognostic significance in adults remains unclear17,18. Whole-exome 
sequencing analysis of 20 adult MLG identified recurrent mutations in TP53, H3F3A 
and ATRX while HIST1H3B and ACVR1 were not found21. Although less frequent, IDH1 
and FGFR1 hotspot mutations represent particular interest in this population21,22, 
because small molecule inhibitors targeting these mutants are being developed and 
there is an urgent need for new treatments in this disease23,24. 
Overall, the genomic landscape of adult MLG remains poorly understood, due to the 
rarity of the disease in this population and the lack of available histological material. 
Indeed, despite growing evidence indicating significant clinical and genomic 
heterogeneity among adult midline tumours25, the need for histological confirmation 
in presence of a typical radiological presentation is often debated, because of the 
morbidity and mortality of surgical procedures in midline locations and assumption 
that histological diagnosis would only have limited impact on therapeutic 
management20. 
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Other mutations in canonical cancer pathways frequently target the receptor tyrosine 
kinase RAS / PI3K pathway (e.g. mutations in PDGFRA, PIK3CA, PIK3R1, or PTEN; 
occurring in -50% of cases), the p53 pathway (e.g. mutations in TP53, PPM1D, CHEK2, 
or ATM; occurring in 70% of cases), and to a lesser extent the retinoblastoma protein 
pathway26-28. Activating mutations or fusions targeting FGFR1 were specifically 
identified in a small proportion of thalamic high-grade gliomas (10%)29. In contrast, 
recurrent mutations in ACVR1, the gene encoding the BMP receptor ACVR1, were 
detected in a subset (-20%) of diffuse intrinsic pontine gliomas (DIPGs), and seem to 
correlate with H3.1 mutations26-28. 
Concerning structural variations, high-level focal amplifications detected in diffuse 
midline gliomas include amplification of PDGFRA (in as many as 50% of DIPGs), 
MYC/MYCN (in as many as 35%), CDK4/6 or CCND1-3(in 20%), ID2 (in 10%), and MET 
(in 7%), whereas homozygous deletion of CDKN2A/B or loss of RB1 or NF1 is detected 
only very rarely (in < 5% of cases)12. Fusion events involving the tyrosine kinase 
receptor gene FGFR1 occur in thalamic diffuse gliomas, and a small proportion (4%) of 
paediatric pontine gliomas have been found to carry neurotrophin receptor (NTRK) 
fusion genes. Common broad chromosomal alterations include single copy gains of 
chromosome 1q and chromosome 2. In addition, there may be a subset of pontine 
gliomas (as many as 20%) that harbour few copy number changes26,28,30. 
 
1.1.1 Diagnosis  
Main clinical signs and symptoms at diagnosis are progressive cognitive disorders and 
focal deficits, seizure (mainly in young patients), increase of intracranial pressure, 
cephalalgy, epilepsy and other behavioural disturbances31. 
The first examination is a computed tomorgaphy (CT) to confirm the presence of a 
lesion. After a positive result, the patient is submitted to magnetic resonance imaging 
(MRI) with contrast to highlight the lesion and its morphology. Then to evaluate the 
metabolic status of the lesion, positron emission tomography (PET) with F-
fluorodeoxyglucose contrast is assessed.  Moreover, in low grade gliomas the uptake 
slightly increases compared to normal tissue, whereas in high grade gliomas, the 
uptake increases significantly. According to these findings, PET results allow glioma 
grading31,32. 
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For the characterization of the tumour, a needle biopsy is required for morphologic 
and molecular biology analyses. This procedure is usually reserved for patients with 
multiple co-morbidities whom could not tolerate a large cranial surgery or for those 
with unresectable tumours due to its location33. 
The algorithm below (Figure 2) shows the workflow assessed for an integrated 
diagnosis of glioma: 
 
 
 
Figure 2.  Algorithm to classify the diffuse gliomas based on histological and genetic features. Genetic 
profile characterization is fundamental to achieve an “integrated” diagnosis. A similar flow can be 
followed for anaplastic level diffuse gliomas (Louis et al., 2016). 
 
According to 2016 WHO and European Association for Neuro-Oncology (EANO) 
guidelines, investigations need to be performed as follows: 
- IDH-status is evaluated by polymerase chain reaction (PCR) and direct 
sequencing; alternatively, immunohistochemistry (IHC) for IDH R132H is 
possible but negative cases need to be confirmed. 
- ATRX loss and TP53 mutation are indirectly detected by IHC; their status is not 
required for the diagnosis, but it may be helpful to substantiate the diagnoses 
of IDH-mutant diffuse astrocytoma and anaplastic astrocytoma;  
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- 1p19q co-deletion is confirmed through a multilocus analysis, like Multiple 
Ligation-dependent Probe Amplification (MLPA); 
- If IDH and 1p19q status are not available, the tumour is diagnosed as 
astrocytoma/anaplastic astrocytoma, NOS or oligodendroglioma/anaplastic 
oligodendroglioma, NOS or glioblastoma, NOS; 
- H3K27M mutation can be detected by IHC using an antibody that recognizes 
the mutated protein or by PCR and direct sequencing.  
Then other markers are evaluated to choose the appropriate treatment to administer 
to patients, like MGMT-promoter methylation status. 
 
1.1.2 Therapy  
Targeted therapy: drugs on clinical trials  
NTRK inhibitors: ongoing trials are testing small-molecules tyrosin kinase inhibitors 
that block Trk activity. The most commonly studied drugs are Entrectinib and 
Larotrectinib, which display a significant antitumour activity with acceptable toxicity 
profile. Larotrectinib is a pan-Trk inhibitor with high specificity34 and Entrectinib binds 
and inhibits TrkA, TrkB, TrkC, ROS1 and ALK35.   
Studies performed on gliomas and non-gliomas cases reported important findings: a 
small percentage of patients showed NTRK fusion as unique genetic alteration known, 
leading to a therapeutically relevant outcome in the future36. 
FGFR inhibitors: inhibitors of FGFR receptor are on clinical evaluation, one of them is 
Erdafitinib (JNJ-42756493), an oral ATP-competitive pan-FGFR selective inhibitor, 
which blocks tyrosine phosphorylation of activated FGFR. There are many other 
molecules that are under pre-clinical and clinical trials that, until now, are displaying 
good outcomes. The future is to develop new therapeutic strategies for IDH-WT 
patients which display a poor prognosis37,38.  
Surgical resection, radio and chemotherapy 
Based on the localization of the gliomas, surgical resection is normally performed. 
After the resection, symptomatology generally disappears, with a good impact on 
patient quality of life. The depth of resection is done in order to preserve motor and 
intellective abilities, or at least, limiting the neurological damage.   
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AIOM 2016 guidelines38 recommend an adjuvant chemotherapy and radiotherapy 
(STUPP protocol). As chemotherapeutic agent is administered TMZ, which is an 
alkylating agent that damages the double-helix of DNA, resulting in apoptosis of 
tumour cells.  
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1.2 Circumscribed gliomas 
Circumscribed gliomas -pilocytic astrocytomas (PA), gangliogliomas (GG), 
ependymomas (EP) and dysembryoplastic neuro-epithelial tumours (DNET)- are 
mostly low-grade tumours but may progress to anaplasia39. These tumours have lower 
genetic complexity40 than diffuse gliomas and therefore could be better candidate for 
targeted therapies, when complete surgical resection is not feasible. 
1.2.1 Pylocitic Astrocytoma 
Pilocytic astrocytomas are the most common glioma in children and adolescents, and 
affect males slightly more often than females (it accounts for 33.2% of all gliomas in 
the 0-14 years age group and 17.6% of all childhood primary brain tumours41). They 
are mainly located in the cerebellum and cerebral midline structures but can be found 
anywhere along the neuraxis; in the paediatric population, more tumours arise in the 
infratentorial region. Preferred sites include the optic nerve (optic nerve glioma), optic 
chiasm/hypothalamus, thalamus and basal ganglia, cerebral hemispheres, cerebellum, 
and brain stem and less frequently in the spinal cord12.  
They are generally circumscribed and slow-growing, and may be cystic. Pilocytic 
astrocytoma largely behaves as is typical of a WHO grade I tumour12, and patients can 
be treated by surgical resection. However, complete resection may not be possible in 
some locations, such as the optic pathways and the hypothalamus. Pilocytic 
astrocytomas, particularly those involving the optic pathways, are a hallmark of 
neurofibromatosis type 1 (NF1). 
In adults, pilocytic astrocytoma tends to arise about a decade earlier (mean patient 
age: 22 years) than does WHO grade II diffuse astrocytoma, but relatively few arise in 
patients aged > 50 years. 
This astrocytic tumour of low to moderate cellularity often has a biphasic pattern, with 
varying proportions of compacted bipolar cells with Rosenthal fibres and loose-
textured multipolar cells with microcysts. The biphasic pattern is best seen in 
cerebellar tumours. However, pilocytic astrocytoma can exhibit a wide range of tissue 
patterns, sometimes several within the same lesion. Although many pilocytic 
astrocytomas are benign, some show considerable hyperchromasia and 
pleomorphism. Rare mitoses are present, but brisk mitotic activity, in particular diffuse 
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brisk mitotic activity, characterizes anaplastic change, which has prognostic 
implications42. 
Genetic profile 
The most frequent abnormality in pilocytic astrocytomas overall (found in > 70% of all 
cases) is an approximately 2 Mb duplication of 7q34, encompassing the BRAF gene. 
This is a tandem duplication resulting in a transforming fusion gene between KIAA1549 
and BRAF43. The N-terminus of the KIAA1549 protein replaces the N-terminal 
regulatory region of BRAF, retaining the BRAF kinase domain, which is consequently 
uncontrolled and constitutively activates the MAPK pathway43. This abnormality is 
found at all anatomical locations, but is most frequent in cerebellar tumours and 
somewhat less common at other sites. The gene fusions involve nine different 
combinations of KIAA1549 and BRAF exons, making identification by RT-PCR or 
immunochemistry difficult, resulting in many centres accepting the demonstration of 
a duplication at 7q34 (usually using FISH probes) as evidence of the KIAA1549-BRAF 
fusion. In addition to harbouring BRAF fusion genes, essentially all pilocytic 
astrocytomas have been shown to have an alteration affecting some component of 
the MAPK pathway44. These alterations include the well-documented NF1 mutations, 
the hotspot BRAF mutation commonly known as the V600E mutation, KRAS mutations, 
alterations of NTRK-family receptor kinase genes and recurrent aberrations affecting 
the FGFR1; they include hotspot point mutations (N546K and K656E), FGFR1-TACC1 
fusions similar to those seen in adult glioblastoma45. 
Concerning genetic susceptibility, pilocytic astrocytomas are the principal CNS 
neoplasm associated with neurofibromatosis 1 (NF1) and approximately 15% of 
individuals with NF1 develop pilocytic astrocytomas, particularly of the optic nerve 
pathways (optic pathway glioma), but other anatomical sites can also be affected. 
Conversely, as many as one third of all patients with a pilocytic astrocytoma of the 
optic nerve have NF112. 
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Figure 3 Left: Estimated frequency of particular MAPK pathway alterations in different anatomic 
locations. Right: Summary showing the MAP kinase pathway with the approximate incidence of the 
different mutations in percent46.  
 
1.2.2 Ependymoma 
Ependymomas are well-circumscribed tumours usually arising in or near the 
ventricular system or spinal canal, in the cerebral hemispheres, or at extra-CNS sites. 
Overall, 60% of the tumours develop in the posterior fossa, 30% in the supratentorial 
compartment, and 10% in the spinal canal 
[http://seer.cancer.gov/archive/csr/1975_2004]. 
Ependymomas can develop in patients of any age, with reported patient ages ranging 
from birth to 81 years [http://www.cbtrus.org]. However, incidence is greatly 
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dependent on histological variant, molecular group, and location. Posterior fossa 
ependymomas are most common among children, with a mean patient age at 
presentation of 6.4 years, and spinal tumours dominate a second age peak at 30-40 
years. Supratentorial ependymomas affect paediatric as well as adult patients12. 
The 10-year overall survival (OS) is about 64% in pediatric patients and ranges from 
70% to 89% in adult patients [http://www.cbtrus.org]. Tumours in infancy are 
associated with a particularly poor survival rate of only 42%– 55% at 5 years after 
diagnosis. The extent of surgical resection has for a very long time been the only 
clinical prognostic marker in EPN known to be associated with survival47. The current 
standard of care includes maximal safe surgical resection, followed by focal 
radiotherapy47. 
Classic ependymoma is a well-delineated glioma with monomorphic cells 
characterized by a variable density and round to oval nuclei with speckled nuclear 
chromatin. The key histological features are perivascular anucleate zones 
(pseudorosettes) and (true) ependymal rosettes; cell density can vary considerably in 
ependymoma. 
A diagnosis of anaplastic ependymoma can be confidently made when an ependymal 
tumour shows a high cell density and elevated mitotic count alongside widespread 
microvascular proliferation and necrosis. Like the classic tumour, anaplastic 
ependymoma rarely invades adjacent CNS parenchyma to any significant extent. 
Traditionally, classic ependymoma and anaplastic ependymoma are considered to 
correspond histologically to WHO grades II and III, respectively. However, no 
association between grade and biological behaviour or survival has been definitively 
established48. 
Genetic profile 
Molecular alterations are very common in ependymoma and comprise cytogenetic, 
genetic, epigenetic, and transcriptomic changes. Ependymomas display a broad range 
of cytogenetic aberrations, most commonly gains of chromosomes 1q, 5, 7, 9, 11, 18, 
and 20 and losses of chromosomes 1p, 3, 6q, 6, 9p, 13q, 17, and 2249,50.  
Using DNA methylation profiling, several studies have provided support for the 
existence of distinct molecular groups among ependymomas51,52. In a large cohort 
(containing > 500 tumours), three groups were identified in each of the three CNS 
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compartments (i.e. supratentorial, posterior fossa, and spinal)52. Tumours with a 
subependymomatous morphology were classified into separate spinal (SP), posterior 
fossa (PF), and supratentorial groups (ST), called SP-SE, PF-SE, and ST-SE, respectively. 
Fusion genes involving either RELA or YAP1 characterize the other two supratentorial 
groups: ST-EPN-RELA and ST-EPN-VAP1. Supratentorial ependymomas are 
characterized by a recurrent structural variant, the C11orf95-RELA fusion gene, which 
is a by-product of chromothripsis and occurs in 70% of paediatric supratentorial 
ependymomas. 
 
1.2.3 Ganglioglioma 
Ganglioglioma is a well-differentiated, slow-growing glioneuronal neoplasm 
composed of dysplastic ganglion cells (i.e. large cells with dysmorphic neuronal 
features, without the architectural arrangement or cytological characteristics of 
cortical neurons) in combination with neoplastic glial cells. Gangliogliomas 
preferentially present in the temporal lobe (70% of cases) of children or young adults 
with early-onset focal epilepsy but these tumours can occur throughout the CNS, 
including brain stem, cerebellum, spinal cord, optic nerves, pituitary, and pineal 
gland12,53. 
BRAF V600E mutation occurs in approximately 25% of gangliogliomas, whereas IDH 
mutation or combined loss of chromosomal arms 1p and 19q exclude a diagnosis of a 
ganglioglioma. The prognosis is favourable, with a recurrence-free survival rate as high 
as 97% at 7.5 years12. 
In anaplastic gangliogliomas, malignant changes almost invariably involve the glial 
component and include increased cellularity, pleomorphism, and increased numbers 
of mitotic figures. Other potential anaplastic features include vascular proliferation 
and necrosis54. 
Genetic profile 
BRAF V600E mutation is the most common genetic alteration in gangliogliomas, 
occurring in 20-60% of investigated cases55,56. This broad range of reported mutation 
frequency is probably related to the sensitivity of the detection methods used, as well 
as the patient age range in the investigated series, given that BRAF point mutations 
are particularly frequent in younger patients57. BRAF V600E is not specific for 
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gangliogliomas and it is also observed in other brain tumours, in particular 
pleomorphic xanthoastrocytomas, pilocytic astrocytomas, and dysembryoplastic 
neuroepithelial tumours55,56. V600E-mutant BRAF protein is localized mainly to 
ganglion cells, but can also be found in cells of intermediate differentiation, as well as 
in the glial compartment, suggesting that ganglion and glial cells in ganglioglioma may 
derive from a common precursor cell57.  
 
1.2.4 Dysembryoplastic neuroepithelial tumour (DNET) 
DNET is a benign glioneuronal neoplasm typically located in the temporal lobe of 
children or young adults with early-onset epilepsy, predominantly with a cortical 
location and a multinodular architecture, and with a histological hallmark of a specific 
glioneuronal element characterized by columns made up of bundles of axons oriented 
perpendicularly to the cortical surface. These columns are lined by oligodendrocyte-
like cells embedded in a mucoid matrix and interspersed with floating neurons. If only 
the specific glioneuronal element is observed, the simple form of DNET is diagnosed. 
Complex variants of DNET additionally contain glial tumour components, often with a 
nodular appearance. Long-term follow-up after epilepsy surgery shows an excellent 
outcome; recurrence or progression is exceptional12. 
Genetic profile 
Paediatric DNETs have been shown to have stable genomes58, whereas recurrent gains 
of whole chromosomes 5 and 7 were found in approximately 20% and 30% of cases, 
respectively, in a series of adult DNETs59. As in other glioneuronal tumours, recurrent 
BRAF V600E mutations were identified in 30% of DNETs. These mutations were 
associated with activation of mTOR signalling60. Neither TP53 mutations nor 
IDH1/IDH2 mutations or H3K27M mutations have been detected in DNETs12. Similarly, 
codeletion of whole chromosome arms 1p/19q has not been demonstrated in 
DNET58,59.  
 
1.3 NTRK genes 
The tropomyosin receptor kinase (Trk) family comprises 3 transmembrane proteins 
named TrkA, TrkB and TrkC receptors that are encoded by neurotrophic tyrosine 
receptor kinase 1, NTRK1 (chromosome 1q23.1), NTRK2 (chromosome 9q21.33) and 
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NTRK3 genes (chromosome 15q25.3), respectively. Gene fusions involving NTRK genes 
encode chimeric Trk proteins with constitutively activated or overexpressed kinase 
function conferring oncogenic potential61. NTRK gene fusions are found in many 
human cancers including tumours of the CNS, mainly in high grade gliomas, referring 
to anaplastic astrocytomas, anaplastic oligodendrogliomas (both WHO grade III) and 
in GBMs (WHO grade IV)62,63. 
Trks are tyrosine kinases receptors expressed in human neuronal tissue and involved 
in development and function of the nervous system through activation by 
neurotrophins (NTs). Trks are structured with an extracellular ligand binding domain, 
a transmembrane region and an intracellular tyrosin kinase domain. The binding of the 
ligand to the receptor triggers the dimerisation of the receptors and phosphorylation 
of specific tyrosine residues in the intracytoplasmic kinase domain. 
TrkA ligand is nerve growth factor (NGF) which activates MAPK pathway and ERK 
signalling (Figure 4). Otherwise this ligand-receptor interaction activates PLCγ and PI3K 
pathways. These are mechanisms that promote survival, differentiation, cell growth 
and preventing apoptosis61. 
TrkB is bound by brain-derived growth factor (BDGF), and NT-4 and NT-5 whereas TrkC 
couples NT-3. These latter receptors activate RAS/MAPK/ERK or PLCγ or PI3K pathways 
resulting in signal transduction pathways leading to proliferation, differentiation and 
survival (Figure 4)63. 
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Figure 4. Schematic view of Trk receptors signalling, showing the three major pathways involved in cell 
differentiation, proliferation and survival63. 
 
NTRK translocations have been found in many tumours and involve the 3’ region of 
the NTRK gene, which contains exons that encode the transmembrane domain (TM) 
and the tyrosine kinase domain (TK). The 3’ region joins with a 5’ sequence of a fusion 
partner gene by a chromosomal rearrangement. More precisely, the ligand binding 
domain is replaced by 5’ fusion partner. When the fusion gene is transcribed, it gives 
rise to an oncogenic chimera that is a constitutively activated or overexpressed 
kinases63. 
NTRK gene fusion have been found initially in paediatric high grade gliomas with a 
recurrence of 40%28 and have been demonstrated that NTRK3 is rearranged with ETS 
variant 6 (ETV6) gene (mapped on 12p13.2 and encoding for a transcription factor), 
while NTRK1 with tropomyosin 3 (TPM3) gene (located on chromosome 1q21.3), both 
these chimeric genes act as oncogenes62. Further studies demonstrated the presence 
of these translocations also in low grade pediatric gliomas and in adult high grade 
gliomas. 
The gene fusions observed in high grade gliomas patients are: 
- TPM3- NTRK1; NFASC-NTRK1; BCAN-NTRK1 in GBMs; 
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- AGBL4-NTRK2; VCAN-NTRK2; VCL-NTRK2 in GBMs; 
- NACC2-NTRK2; QKI-NTRK2 in astrocytomas; 
- ETV6-NTRK3; BTBD1-NTRK3 in GBMs. 
All of them confers an oncogenic behaviour to fusion proteins28. 
NTRK gene fusions are common in children affected by diffuse intrinsic pontine glioma 
(DIPG)28. NTRK fusion genes in children <3 years old affected by high grade gliomas are 
associated to the paucity of additional mutations, and the rapid tumour onset, strongly 
suggest that these fusion genes are potent oncogenic drivers in early postnatal brain 
tumour development. Recently, the identification of NTRK fusions, also in other solid 
tumours, come into focus due to the availability of targeted therapies like NTRK 
inhibitors63. 
 
1.4 FGFR1 gene 
FGFR genes control many biological functions, including cell proliferation, survival, and 
cytoskeletal regulation. FGFRs signaling is important during embryonal development 
of the CNS, and as a survival mechanism for adult neurons and astrocytes and promote 
self-renewal and fate specification of neural stem cells64. 
In many cancers, FGFRs aberrations have been implicated in tumour development and 
progression65,66, and include FGFRs overexpression, amplification, mutations, splicing 
isoform variations, and FGFRs translocations67. While FGFRs genomic alterations have 
been identified in many solid tissue cancers, such events remain rare in glioblastoma 
(GBM)68. Nonetheless, FGFRs expression changes in astrocytes can lead to malignant 
transformation and GBM progression due to the activation of mitogenic, migratory, 
and antiapoptotic responses69. Of note, fusions between FGFRs and TACCs 
(transforming acidic coiled-coil containing proteins) genes were shown to be 
oncogenic in GBM70, and occur in about 3% of GBM patients68. Whole-genome 
analyses of patient samples have revealed that the number of FGFRs mutations and 
amplifications are generally very low in GBM (FGFR1: 51/3068 samples, FGFR2: 
12/2662; FGFR3: 16/2887; FGFR4: 9/2456; cancer.sanger.ac.uk).  
Moreover, the expression of FGFR1 increases with WHO grade in astrocytomas, and 
increased FGFR1 levels in GBM are not due to amplification of the FGFR1 gene64. 
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Functionally, FGFR1 expression in malignant glioma has been associated with 
increased migration of cancer cells71. In this study, a high expression of EPHA4 in 
glioma cells was found to potentiate FGF2–FGFR1 signaling and promoted cell growth 
and migration through the AKT/MAPK and RAC1/CDC42 pathways, respectively.  
Loilome and colleagues72 identified FGFR1 as a potential transducer of FGF2 effects on 
glioma cell proliferation, but whether other FGFRs also contribute was not directly 
tested. Nevertheless, the pharmacological inhibition of FGFRs signaling significantly 
reduced tumour cell growth in a range of established and patient-derived glioma lines. 
The malignancy-promoting effects of FGFR1 were further demonstrated in a study that 
found FGFR1 signaling promoting radioresistance in glioma cell lines through PLC1γ 
and HIF1α73. FGFR1 expression is regulated by the stem-cell associated transcription 
factor ZEB1, suggesting that FGFR1 may be associated with GBM cancer stem cells. A 
comprehensive analysis of the functions of FGFR1-3 in GBM found that FGFR1 indeed 
is preferentially expressed on GBM cancer stem cells, where it regulates the 
expression of the critical stem cell transcription factors SOX2, OLIG2, and ZEB1, 
thereby promoting tumourigenicity in vivo74. In summary, FGFR1 is a key regulator of 
tumour growth, invasion, therapy resistance, and cancer stemness in malignant 
glioma.  
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2. AIM OF THE STUDY 
 
Since midline gliomas are one of the more aggressive tumours of CNS and generally 
unresectable, the aim of this study is to contribute to unravel the genomic landscape 
of this heterogeneous group of gliomas  in order to better define the prognostic value 
of molecular biomarkers and identify new therapeutic strategies that could improve 
patient care. Recently, a new class of tyrosine kinase inhibitors has been introduced in 
clinical trials. For this reason, we investigated the presence of FGFR1 mutations and 
NTRK gene rearrangements in order to explore the frequency, the possible correlation 
with clinical, histologic and genomic features and also the feasibility of testing in the 
diagnostic routine analysis to allow a possible future use of targeted therapies in 
clinical practice. 
Moreover, since there is a scant literature about FGFR1 mutation rate in rarer CNS 
tumours like pilocytic astrocytoma, ganglioglioma, dysembryoblastic neuroepithelial 
tumour and ependymoma and also specific inhibitors are available in clinical trials, our 
idea is to investigate these mutational hotspots in a cohort of circumscribed gliomas. 
This information could be helpful in defining different therapeutic strategies when 
surgery is not feasible.  
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3. MATERIAL AND METHODS  
 
3.1 Sample collection  
3.1.1. Midline Gliomas 
Patients (>15 years) with diagnosis of MLG were retrospectively identified from each 
institution’s databases (OncoNeuroTek tumour bank, GH Pitié-Salpêtrière, (Paris, 
France) and AOU Maggiore della Carità, SCDU Anatomia Patologica (Novara, Italy)) 
between 1996 – 2017 for the French cohort and from 1993 to 2017 for the Italian 
cohort. For two patients (Italian cohort) the primary tumour and the recurrent tumour 
were collected.  
Inclusion criteria were as follows:  
(1) tumour arising in midbrain location (thalamus, hypothalamus, pineal region, 
brainstem, cerebellum or spinal cord), verified on neuroimaging at diagnosis; 
(2) histopathological confirmation of diffuse glioma according to WHO 2016 
classification; 
(3) available follow-up data.  
All tumour samples underwent histopathological review.  
The French cohort has been analyzed previously75 to the Italian one and it has been 
considered as a starting point for subsequent analyses. 
 
3.2.1 Circumscribed gliomas 
Patients (>15 years) with diagnosis of pilocytic astrocytoma (PA), ganglioglioma (GG), 
dysembryoblastic neuroepithelial tumour (DNET) and ependymoma (EP) were 
retrospectively identified from each institution’s databases (Onconeurotek tumour 
bank GH Pitié-Salpêtrière, (Paris, France), and “AOU Maggiore della Carità, SCDU 
Anatomia Patologica (Novara, Italy)) according to the histopathological diagnosis.  All 
tumour samples underwent histopathological review. 
 
All tumour samples and clinical data were collected in accordance with the tenets of 
the Declaration of Helsinki. 
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3.2 Tissue microarray  
Tissue microarray (TMA) technique allow to handle up to several samples in one block 
or in one slide as it may contain hundreds of small different and representative tissue 
samples on a single paraffin block. These samples are obtained by the extraction of a 
tissue core of 1.5 mm of diameter, by using a holed needle, from “donor blocks” and 
re-embedded all together in a single empty block, called “recipient block”, at defined 
coordinates. In the array are also put other tissues (like liver) as references for the 
orientation of the array.  
At first, haematoxylin-eosin (H&E) stained slides of each sample that will be included 
in the TMA are required to select the most significant tumour areas avoiding normal 
brain tissue, necrosis or haemorrhagic regions. For each sample, 1 to 3 areas have 
been selected for TMA construction by marking on the H&E slide, depending on the 
extension of the tumour area. The marked H&E slide is necessary for the alignment of 
the selected areas to the corresponding FFPE block. The alignment is done through a 
PC connected to the instrument TMA Master (3DHISTECH LTD) and the software used 
is TMA Master 1.14 SP3 (3DHISTECH LTD).  After that, the same instrument takes tissue 
cores from FFPE samples (donor blocks), and then all the cores are re-embedded in 
one single recipient block.  
TMA was constructed only for midline gliomas belonging to the Italian cohort. In our 
recipient block are present 107 samples cores and 8 liver cores used as orientation 
references.  
TMA construction was performed by the team of Dr. Milo Frattini at Istituto Cantonale 
di Patologia (Locarno, Switzerland). 
For the following steps, 4 µm sections from the recipient block are cut using the 
microtome and put on a positively charged glass slide in order to perform FISH analysis 
and immunohistochemistry stainings. 
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3.3 DNA extraction and quantification 
Genomic DNA of GH Pitié-Salpêtrière’s cases was extracted from formalin-fixed 
paraffin-embedded (FFPE) or frozen samples, as previously described75. Genomic DNA 
of patients from Maggiore della Carità Hospital were extracted from five 5μm sections 
of FFPE samples by the GeneRead DNA FFPE Kit (Qiagen) on the QIAcube automatic 
extractor (Qiagen) according to the manufacturer’s protocol. 
 
3.3 Sanger sequencing 
Hotspot mutation regions of IDH1 (codon 132), IDH2 (codon 172), TERT promoter 
(positions -250 and -228), FGFR1 exons 12 (codon 546) and 14 (codon 656), H3F3A 
(codons 27 and 34), HIST1H3B (codon 27) and BRAF exon 15 (codon 600) were 
amplified by standard PCR amplification and sequenced by Sanger sequencing. Primer 
sequences are reported in Table 1. 
  
Figure 5. Schematic description of TMA technique. 
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Gene   Sequence 5'-->3' 
IDH1 Forward TGTGTTGAGATGGACGCCTATTTG 
Reverse TGCCACCAACGACCAAGTCA 
IDH2 Forward GCCCGGTCTGCCACAAAGTC 
Reverse TTGGCAGACTCCAGAGCCCA 
H3F3A Forward GTGATCGTGGCAGGAAAAGT 
Reverse CAAGAGAGACTTTGTCCCATTTT 
HIST1H3B Forward GTTTTGCCATGGCTCGTACT 
Reverse AAGCGAAGATCGGTCTTGAA 
FGFR1 exon 12 Forward CCTCCTCCCTTCCCAAGTAA 
Reverse GGACTGATACCCCAGCTCAG 
FGFR1 exon 14 Forward CTTCCAGCTCCCTCACCTC 
Reverse CCCACTCCTTGCTTCTCAGAT 
TERT promoter Forward TCCTGCCCCTTCACCTT 
Reverse AGCACCTCGCGGTAGTGG 
BRAF Forward TGCTTGCTCTGATAGGAAAATG 
Reverse CAGGATCTCAGGGCCAAAAAT 
Table 1. Primers’ sequences 
 
All PCR amplifications were performed at 3 minutes at 94°C; 35 cycles at 94°C 15 
seconds, 60°C 45 seconds, 72°C 1 minute, with a final step at 72°C for 8 minutes.  
PCR reactions were set up with AmpliTaq Gold 360 MasterMix (Thermo Fisher) 1x, 
500nM of each primer and only for TERT promoter amplification, 10% 360 GC 
enhancer (Thermo Fisher).  
Sequencing reactions were performed with BigDye Terminator v.1.1 (Thermo Fisher) 
and analysed on the sequencer 3130 Genetic Analyser (Applied Biosystems). 
 
3.4 Fluorescence in situ hybridization (FISH) 
FISH analyses were perfomed by using NTRK1, NTRK2 and NTRK3 break-apart probes 
(ZytoLight SPEC Dual Color Break Apart probes, ZytoVision).  
NTRK1 probe is a mixture of two direct labelled probes hybridizing to the 1q22-q23.1 
band (Figure 6). The green fluorochrome direct 
labelled probe hybridizes proximal and the red 
fluorochrome direct labelled probe hybridizes distal 
to the NTRK1 gene. 
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NTRK2 probe is a mixture of two direct labelled probes hybridizing to the 9q21.32-
q21.33 band (Figure 7). The green fluorochrome 
direct labelled probe hybridizes proximal to the 
NTRK2 breakpoint region at 9q21.32-q21.33, the red 
fluorochrome direct labelled probe hybridizes distal 
to the NTRK2 breakpoint region at 9q21.33. 
 
NTRK3 probe is a mixture of two direct labelled probes hybridizing to the 15q25.3-
q26.1 band (Figure 8). The orange fluorochrome 
direct labelled probe hybridizes proximal to the 
NTRK3 breakpoint region at 15q25.3, the green 
fluorochrome direct labelled probe hybridizes distal 
to the NTRK3 breakpoint region at 15q25.3-q26.1. 
 
The result interpretation is equal for all the 3 probes. If there is a translocation, the 2 
fluorescent signals (green and red) are separated and there are 2 distinct colours 
coupled with a fusion signal corresponding to the wild-type allele. If there is no 
translocation the 2 signals appear as a fusion signal, for a total of 2 fusion signals/cell. 
 
FISH protocol    
4 µm thick sections of the FFPE tissue or TMA need to be cut and put on polarized 
(positively charged) slides. For each patient or TMA, 3 sections were cut, 1 for each 
gene analysis (NTRK1, NTRK2 and NTRK3). 
Deparaffination: slides are incubated into a dry heat oven at 60°C overnight (ON). The 
day after, tissues are re-hydrated through xylene and decreasing alcoholic series (10’ 
xylene, 10’ xylene, 5’ 100% alcohol, 5’ 95% alcohol, 5’ 80% alcohol, 5’ 75% alcohol, 5’ 
deionized water).  
Pretreatment: incubation in pre-heated Heat Pretreatment Solution (ZytoLight FISH-
Tissue Implementation Kit, ZytoVision) at 92°C for 20’. Then the slides are brought to 
Figure 6. NTRK1 probe map (not to 
scale). 
Figure 7. NTRK2 probe map (not to 
scale). 
Figure 8. NTRK3 probe map (not to 
scale). 
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room temperature (RT) in deionized water for 5’. Subsequently, the slides are air-
dried.  
Tissue digestion: incubation with Pepsin Solution (ZytoLight FISH-Tissue 
Implementation Kit, ZytoVision) is performed for 4’-7’ at 37°C in a hybridizer 
(TopBrite™, Resnova) with humidity chamber.  After that slides are washed in Wash 
Buffer SSC (ZytoLight FISH-Tissue Implementation Kit, ZytoVision) for 5’ at RT and then 
5’ in deionized water. Tissues are dehydrated (1’ 75% alcohol, 1’ 80% alcohol, 1’ 95% 
alcohol, 1’ 100% alcohol), then DAPI and coverslips are applied, and tissue digestion is 
checked by fluorescence microscope. If the tissue is digested enough (only nuclei are 
visible without cytoplasm and membranes) DAPI and coverslips are removed with 
Wash Buffer SSC (ZytoLight FISH-Tissue Implementation Kit, ZytoVision) for 5’ at RT 
and 5’ in deionized water. Since the probes used are hydrophobic, it is necessary to 
dehydrated through increasing alcoholic series (1’ 75% alcohol, 1’ 80% alcohol, 1’ 95% 
alcohol, 1’ 100% alcohol). Then sections are air-dried.  
Probe hybridization: 5 µl of each probe are applied for each section (protecting from 
light) coverslip is applied and sealed with Fixo-gum (Marabu, Germany) to keep the 
probe on the section and avoid its evaporation. Glass slides are put into the hybridizer 
(TopBrite™) with humidity chamber and denaturated for 10’ at 75°C and then 
hybridized at 37°C ON.  
Stringency washes and mounting: the day after, coverslips are removed and stringency 
washes are performed with 1X Wash Buffer SSC (ZytoLight FISH-Tissue 
Implementation Kit, ZytoVision), 2x5’at 37°C. Then tissues are dehydrated (1’ 75% 
alcohol, 1’ 80% alcohol, 1’ 95% alcohol, 1’ 100% alcohol), air-dried and counterstained 
with DAPI. FISH are ready and fluorescence can be detected through fluorescence 
microscope.   
Fluorescence acquisition: fluorescent signals were acquired by using the Axioplan2 
microscope (Zeiss) coupled with AxioCam HRm (Zeiss) camera and AxioVision software 
(Zeiss) for images acquisition. We acquired 3 fluorescences (FITC, Rhodamine and DAPI 
channels) for each high-power field at 63x (oil immersion).  For each sample, we 
analysed at least 6 high-power fields and a minimum of 100 cells for each case across 
all the respective cores in the TMA.  
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Up to now, there are not present any guidelines that establish a specific cut-off (% 
positive cells) for NTRK rearrangements. We considered as positive, cases with any 
percentage of positive cells; positivity is considered when contiguous cells report a 
signal pattern consisting of one orange/green fusion signal, one separate orange signal 
and one separate green signal (ZytoVision).  
 
3.5 Immunohistochemistry 
ATRX expression analysis in samples of the Italian cohort were performed by 
immunohistochemistry on a Ventana BenchMark ULTRA automated platform (Roche 
Diagnostics) coupled with ultraView Universal DAB Detection Kit (Ventana Medical 
Systems – Roche). A rabbit polyclonal antibody (HPA001906, Sigma-Aldrich) was used 
at 1:400 dilution, 90’ antigen retrieval with CC1 buffer (Ventana Medical Systems – 
Roche), 60’ antibody incubation and signals were amplified with the Amplification kit 
(Ventana Medical Systems – Roche).  
 
3.6 Other analyses 
Cases belonging to the French cohort of MLG were previously analysed for ATRX and 
p53 nuclear expression by immunohistochemistry, CDKN2A/p16 loss and EGFR 
amplification at GH Pitié-Salpêtrière (Paris)75. 
 
3.7 Statistical analysis  
Continuous variables have been described with mean and standard deviation, 
categorical variables with counts and percentages. The distributions of the categorical 
variables within the groups were analysed with the chi-square test or with the Fisher 
exact test. 
The distributions of continuous variables within the groups of interest were analysed 
with the independent t-student test. 
The survival curves were obtained according to the Kaplan Meier method and were 
compared with the log-rank test. 
P-values <0.05 were considered statistically significant. All the analyses were 
performed with the STATA15 software. 
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4. RESULTS 
4.1 Molecular characteristics of French and Italian cohort of midline gliomas 
Patients characteristics and tumour main molecular alterations, according to the 
location are reported in Table 2. 
The two cohorts showed different distribution in the location of the tumour as well as 
in the percentage of H3F3A mutations. In the French cohort, histone H3K27M 
mutation was found in 38/110 patients (34%) and was significantly associated with a 
younger age at diagnosis (median 33 years vs. 53 years, p=6*10-5). In Italian cohort, 
H3F3A  mutations were identified in 20% of cases and there was not seen any 
association with a younger age, probably due to the lower number of mutated cases. 
H3K27M mutation were mutually exclusive with IDH1, and inversely associated with 
TERTp mutation in both cohorts. H3K27M was found in all the locations but was 
significantly associated with thalamic and spinal locations in French cases; this 
evaluation did not reach any statistically significant differences in the Italian cohort 
due to the low number of mutated cases (Table 3). 
In the French cohort, IDH1 mutations were found in 6 patients (1 grade II, 4 grade III, 
1 grade IV) out of 102: strikingly, all 6 IDH1 mutated tumours were located in 
brainstem (6/24 vs. 0/78 for MLG not involving the brainstem; p=7.5.10-5). 
Noteworthy, only one out of the 5 IDH1 mutation identified by sequencing was IDH1 
p.Arg132His (R132H), the other mutations were p.Arg132Gly (R132G), p.Arg132Cys 
(R132C), p.Arg132Leu (R132L), p.Arg132Gly (R132G), which contrasted with non-
midline IDH1-mutant gliomas. Also in the Italian cohort is present a non-canonincal 
IDH1 mutation (R132G) in two cases (astrocytoma grade II of the ventricle) belonging 
to the same patient (primary and recurrent tumour). 
According to the 2016 WHO classification, all H3K27M mutated MLG were considered 
as grade IV tumours. However, we did not find any impact of histone H3K27M 
mutation in terms of overall survival in both cohort. Analysing the impact of specific 
alterations on survival, the French cohort showed that IDH1 mutation, loss of ATRX 
and FGFR1 mutations were associated with longer survival while the Italian cohort did 
not show any statistically significant differences within these gene alterations, 
probably due to the lower number of cases, but only with a poor survival in pTERT 
mutated cases (Figure 9, also reported in the French cohort).  
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Figure 9. Kaplan Meier curve of pTERT mutated vs wild-type cases (Italian cohort). The red line 
represents the C228T mutation, the green line the C250T mutation and the blue line the wild-type 
cases. 
 
FGFR1 mutation analysis 
Recurrent FGFR1 mutations affecting two hotspots were identified in 18% of patients 
(13/73) in the French cohort: p.Asn546Lys (9), p.Asn546Asp (2), p.Lys656Glu (2) with 
diverse locations: 7/37 thalamus (19%), 2/12 brainstem (17%), 2/13 cerebellar (15%), 
1/3 spinal cord (33%) (p=0.9), in both H3K27M MLG (6/23) and histone wild-type MLG 
(6/45); p=0.3; 6/41 IDH wildtype vs. 0/4 IDH mutated, p=1. In order to investigate 
whether FGFR1 mutation were specific to midline diffuse gliomas, we sequenced from 
OncoNeuroTek tumour bank 479 DNA samples extracted from unselected 
hemispheric gliomas (170 GBM, 151 grade III, 157 grade II; of which, 197 were IDH 
mutated, 212 IDH wild type, and 70 undetermined) for the presence of FGFR1 
mutations: we found only one mutation in a patient with an IDH wildtype GBM 
involving the corpus callosum, suggesting that FGFR1 mutations are restricted to 
midline diffuse gliomas (13/73 vs. 1/479; p=1.2.10-10). This data were further 
confirmed by public data (http://www.cbioportal.org): out of 1722 patients with 
diffuse gliomas, only 2 patients had FGFR1 activating mutation (13/73 vs. 2/1722; 
p=10-16): one GBM with K656E mutation but no clinical information on location and 
one 1p/19q-codeleted IDH1 mutant frontal oligodendroglioma with N546K mutation. 
In the Italian cohort, FGFR1 mutations were found only in 3/46 cases (7%), all 
p.Lys656Glu mutations (1 GBM-H3K27M of the III ventricle, 1 anaplastic 
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oligodendroglioma-H3K27M of the parasellar region and 1 intramedullary anaplastic 
astrocytoma). These cases were wild-type for IDH1/2, TERT promoter and BRAF, while 
2 out of 3 cases were H3F3-K27M mutated.
32 
 
 
 
  
French Cohort Italian Cohort 
Total 
 Non-
thalamic 
diencephalic 
Thalamic Brainstem Cerebellar  Spinal cord Total 
 Non-
thalamic 
diencephalic 
Thalamic Brainstem Cerebellar  Spinal cord 
N, % (n) 116 4 (4/116) 48 (57/116) 26 (30/116) 15 (17/116) 7 (8/116) 46 27/46 5/46 1/46 5/46 8/46 
Sex ratio (M/F) 1.58 (71/45) 3 (3/1) 
1.38 
(33/24) 2.33 (21/9) 1.13 (9/8) 1.67 (5/3) 
1.71 
(29/17) 2 (18/9) 0.7 (2/3) 1 (1/0) 1.5 (3/2) 1.67 (5/3) 
Age at surgery in 
years, median 
(range) 
46.5 (15 – 
75) 
55.5 (46 - 
66) 49 (15 - 75) 
41.5 (22 - 
75) 50 (23 - 73) 34.5 (18 - 57) 46 (16-81) 45 (21-69) 51 (28-69) 17 49 (24-81) 49 (17-63) 
Histology according 
to 2016 WHO 
classification, % (n) 
                        
Grade II 10 (12/116) 0 12 (7/57) 13 (4/30) 6 (1/17) 0 (0/8) 24 (11/46) 26 (7/27) 20 (1/5) 0 0 38 (3/8) 
diffuse astrocytoma, 
IDH mutant 1 (1/116) 0 0 (0/57) 3 (1/30) 0 0 4 (2/46) 7 (2/27) 0 0 0 0 
diffuse astrocytoma, 
IDH wild type 6 (7/116) 0 11 (6/57) 3 (1/30) 0 0 20 (9/46) 19 (5/27) 20 (1/5) 0 0 38 (3/8) 
diffuse astrocytoma, 
NOS 3 (3/116) 0 2 (1/57) 3 (1/30) 6 (1/17) 0 0 0 0 0 0 0 
oligodendroglioma, 
IDH mutant and 
1p/19q codeleted 
0 0 0 0 0 0 0 0 0 0 0 0 
oligodendroglioma, 
NOS 0 0 0 0 0 0 0 0 0 0 0 0 
oligoastrocytoma, 
NOS 1 (1/116) 0 0 3 (1/30) 0 0 0 0 0 0 0 0 
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Grade III 15 (17/116) 0 9 (5/57) 33 (10/30) 0 25 (2/8) 17 (8/46) 22 (6/27) 40 (2/5) 0 40 (2/5) 38 (3/8) 
anaplastic 
astrocytoma, IDH 
mutant 
3 (4/116) 0 0 13 (4/30) 0 0 2 (1/46) 4 (1/27) 0 0 0 0 
anaplastic 
astrocytoma, IDH 
wild type 
8 (9/116) 0 7 (4/57) 13 (4/30) 0 13 (1/8) 15 (7/46) 15 (4/27) 20 (1/5) 0 40 (2/5) 38 (3/8) 
anaplastic 
astrocytoma, NOS 3 (3/116) 0 0 7 (2/30) 0 13 (1/8) 0 0 0 0 0 0 
anaplastic 
oligodendroglioma, 
IDH mutant and 
1p/19q codeleted 
0 0 0 0 0 0 0 0 0 0 0 0 
anaplastic 
oligodendroglioma, 
NOS 
0 0 0 0 0 0 4 (2/46) 4 (1/27) 20 (1/5) 0 0 0 
anaplastic 
oligoastrocytoma, 
NOS 
0 0 0 0 0 0 0 0 0 0 0 0 
high grade glioma in 
NF1 1 (1/116) 0 2 (1/57) 0 0 0 0 0 0 0 0 0 
Grade IV 75 (87/116) 100 (4/4) 79 (45/57) 53 (16/30) 94 (16/17) 75 (6/8) 48 (22/46) 52 (14/27) 40 (2/5) 1 60 (3/5) 25 (2/8) 
glioblastoma, IDH 
mutant 1 (1/116) 0 0 3 (1/30) 0 0 0 0 0 0 0 0 
glioblastoma, IDH 
wild type 37 (43/116) 0 37 (21/57) 20 (6/30) 76 (13/18) 0 48 (22/46) 52 (14/27) 40 (2/5) 1 60 (3/5) 25 (2/8) 
glioblastoma, NOS 2 (2/116) 75 (3/4) 2 (1/57) 0 6 (1/17) 0 0 0 0 0 0 0 
Diffuse midline 
glioma, H3 K27M 
mutant 
35 
(41/116) 25 (1/4) 40 (23/57) 30 (9/30) 12 (2/17) 75 (6/8) 20 (9/46) 4 1 1 0 3 
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Table 2. Patients characteristics and tumour main molecular alterations, according to the location.  
 
 
 
 
Median OS in 
months (95% CI) 
17.3 
months 
(14.5 – 
23.8 
months) 
8.2 months 
(0.3 - NA 
months) 
17.3 
months 
(14.5 – 27.5 
months) 
16.3 
months 
(11.6 – 52.2 
months) 
19.7 
months (8.3 
– NA 
months) 
23.0 months 
(3.8 – NA 
months) 
43.7 
months 34.6 months 
39.7 
months 
6.8 
months NA 49 months 
IDH mutation, % (n) 6 (6/102) 0 0 25 (6/24) 0 0 9 (4/46) 12 (3/27) 0 0 0 0 
IDH1 100 (6/6) 0 0 100 (6/6) 0 0 100 (4/4) 100 (3/3) 0 0 0 0 
IDH2 0 0 0 0 0 0 0 0 0 0 0 0 
K27M mutation, % 
(n) 
34 
(38/111) 25 (1/4) 40 (22/55) 29 (8/28) 12 (2/17) 71 (5/7) 20 (9/46) 15 (4/27) 20 (1/5) 100 (1/1) 0 38 (3/8) 
 H3F3A 79 (30/38) 100 (1/1) 86 (19/22) 37 (3/8) 100 (2/2) 100 (5/5) 100 (9/9) 100 (4/4) 100 (1/1) 100 (1/1) 0 100 (3/3) 
HIST1H3B 3 (1/38) 0 0 13 (1/8) 0 0 0 0 0 0 0 0 
NA (IHC only) 18 (7/38) 0 14 (3/22) 50 (4/8) 0 0 0 0 0 0 0 0 
ATRX loss, % (n) 19 (16/86) 0 16 (7/45) 30 (6/20) 17 (2/12) 20 (1/5) 20 (9/46) 19 (5/27) 40 (2/5) 0 40 (2/5) 0 
pTERT mutation, % 
(n) 37 (32/86) 66 (2/3) 40 (19/47) 38 (6/16) 23 (3/13) 29 (2/7) 35 (16/46) 37 (10/27) 60 (3/5) 0 40 (2/5) 1 
C228T: 78 (25/32) 100 (2/2) 74 (14/19) 83 (5/6) 67 (2/3) 100 (2/2) 50 (8/16) 80(8/10) 0 0 0 0 
C250T: 25 (8/32) 0 25 (5/19) 33 (2/6) 33 (1/3) 0 50 (8/16) 20 (2/10) 100 (3/3) 0 100 (2/2) 100 (1/1) 
FGFR1 mutation, % 
(n) 19 (13/70) 0 18 (7/38) 23 (3/13) 15 (2/13) 33 (1/3) 7 (3/46) 7 (2/27) 0 0 0 12 (1/8) 
EGFR amplification, 
% (n) 12 (7/57) NA 11 (3/28) 10 (2/20) 40 (2/5) 0 NA NA NA NA NA NA 
p16/CDKN2A loss, % 
(n) 19 (11/57) NA 21 (6/28) 15 (3/20) 40 (2/5) 0 NA NA NA NA NA NA 
BRAF V600E 
mutation, % (n) 0 0 0 0 0 0 2 (1/46) 0 20 (1/5) 0 0 0 
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French Cohort Italian Cohort 
  K27M  wild type K27M mutated P-value   
K27M  
wild type 
K27M 
mutated P-value   
N 73 38 NA 37 9   
Sex ratio (M/F) 1.52 (44/29) 1.53 (23/15) 0.98 1.64 (23/14) 2 (6/3)  0.58 
Age at surgery in years, median (range) 53 (23 – 75) 33 (15 – 65) <0.0001 48 (17-81) 39 (16-69)  0.11 
Location, % (n)             
-              Non-thalamic diencephalic 4 (3/73) 3 (1/38)   62 (23/37) 44 (4/9)   
-              Thalamic 45 (33/73) 58 (22/38)   11 (4/37) 11 (1/9)   
-              Brainstem 27 (20/73) 21 (8/38) 0.04 0 11 (1/9)  0.12 
-              Cerebellar 21 (15/73) 5 (2/38)   13.5 (5/37) 0   
-              Spinal cord 3 (2/73) 13 (5/38)   13.5 (5/37) 33 (3/9)   
Median OS in months 15.0 months 18.6 months 0.65 51.7 months 17.2 months  0.59 
IDH mutation, % (n) 17 (5/30) 0 0.16 11 (4/37) 0  0.49 
ATRX loss, % (n) 15 (8/54) 26 (8/31) 0.25 22 (8/37) 11 (1/9)  0.47 
pTERT mutation, % (n) 52 (27/52) 19 (5/27) 
0.007 
44 (16/37) 0 
 0.027 -              C228T: 20 4 8   
-              C250T: 7 1 8   
FGFR1 mutation, % (n) 13 (6/46) 26 (6/23) 0.19 3 (1/37) 22 (2/9)  0.11 
BRAF mutation, % (n) 0 0 NA 3 (1/37) 0  1.00 
 
Table 3. Clinical, histological and molecular characteristics in patients with H3K27M versus H3K27wt MLG   
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4.2 NTRK gene analysis in MLG 
4.2.1 NTRK1 status 
The Italian cohort of MLG was investigated for NTRK genes rearrangements. 
In five cases out of 45 (11.1%) the analysis failed due to tissue artifacts (pre-analytical 
problems). 
NTRK translocations were detected in 6 (15%) cases. Concerning case 2, we have 
selected and analysed primary (case 2A) and recurrent (case 2B) tumours. For 
statistical analysis the case number 2 were considered as a single case.  
Clinical and genomic profiling of the 6 translocated reported: 4 (66,7%) males and 2 
(33.3%) females, 43 year as mean age of diagnosis, 2 (33.3%) cases localized in lateral 
ventricle, 1 (16.67%) in thalamus, 1 (16.67%) in brainstem, 1 (16.67%) involving corpus 
callosum and 1 (16.67%) in spinal cord. Two cases (33.3%) were histological diagnosed 
as grade II astrocytoma (according to 2016 WHO classification) and 4 (66,7%) cases as 
GBMs. Five cases (83.3%) did not show IDH1 mutations, 1 case (16.67%) harbour 
R132G mutation in IDH1. None IDH2 mutations were identified. In one case (16.67%) 
G34R and R26H mutations were present in H3F3A gene, 2 (33.3%) cases showed K27M 
mutation in H3F3A and 3 (50%) cases were WT. All cases (100%) did not show 
mutations in HIST1H3B, FGFR1 (exon 12 and 14) and BRAF (exon 15). One case 
(16.67%) harboured pTERT C250T mutation, 1 case (16.67%)  showed C228T and 4 
cases (66,7%) were WT. Concerning ATRX status, 3 cases (50%) showed protein loss 
and in 3 cases (50%) ATRX expression is retained in the nucleus.  
Regarding NTRK1, the percentages of cells showing NTRK1 translocation were: 38% in 
case 1, 29% and 20% respectively in case 2A and 2B, 25% in case 3, 29% in case 4, 34% 
in case 5 and 17% in case 6.  
In Table 4, detailed genomic profiling and protein expression of the 6 translocated 
cases are shown.  
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Table 4. Molecular profiling and protein expression of the 6 NTRK1 translocated cases. 
Case Gender Tumour 
Age at 
diagnosis 
Localization Diagnosis IDH1 IDH2 H3F3A HIST1H3B 
FGFR1 
ex. 12 
FGFR1 
ex. 14 
BRAF pTERT ATRX NTRK1 
1 M Primary 30 Lateral ventricle A2 WT WT 
G34R + 
R26H WT WT WT WT WT LOSS 38% 
2A M Primary 43 Lateral ventricle  A2 R132G WT WT WT WT WT WT WT LOSS 29% 
2B M Recurrence 47 Lateral ventricle A2 R132G WT WT WT WT WT WT WT LOSS 20% 
3 F Primary 69 Thalamus GBM WT WT WT WT WT WT WT C250T LOSS 25% 
4 M Primary 16 Brainstem GBM WT WT K27M WT WT WT WT WT RETAINED 29% 
5 M Primary 68 Corpus callosum GBM WT WT WT WT WT WT WT C228T RETAINED 34% 
6 F Primary 31 Spinal cord GBM WT WT K27M WT WT WT WT WT RETAINED 17% 
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The comparison between NTRK1 positive and negative cases are reported in Table 5. 
 
  
NTRK1 translocation 
Negative Positive P-value   
N 35 6  NA 
Sex ratio (M/F) 1.69 (22/13) 0.5 (2/4)  1.000 
Age at surgery in years, median (range) 47 (17 – 81) 43 (16 – 69)  1.000 
Location, % (n)     
 0.218 
-              Non-thalamic diencephalic 57 (20/35) 50 (3/6) 
-              Thalamic 9 (3/35) 17 (1/6) 
-              Brainstem 0 17 (1/6) 
-              Cerebellar 14 (5/35) 0 
-              Spinal cord 20 (7/35) 17 (1/6) 
Diagnosis, % (n) 
46 (16/35) A2-3 33 (2/6) A2 
 0.640  6 (2/35) OD3 66 (4/6) GBM 
48 (17/35) GBM   
Median OS in months 50.4 months 18.7 months  0.095 
IDH mutation, % (n) 3 (1/35) 17 (1/6)   
ATRX loss, % (n) 14 (5/35) 50 (3/6)  0.268 
pTERT mutation, % (n) 34 (12/35) 33 (2/6) 
 1.000  C228T (n): 6 1 
 C250T (n): 6 1 
H3F3A-K27M mutation, % (n) 20 (7/35) 33 (2/6)  0.607 
FGFR1 mutation, % (n) 9 (3/35) 0  1.000 
BRAF mutation, % (n) 3 (1/35) 0  1.000 
Table 5. Clinical, histological and molecular characteristics in patients with NTRK1 translocated versus 
NTRK1 not-translocated MLG 
 
The Fisher exact test did not find any correlation among NTRK1 gene rearrangements 
and clinical-pathological data (age, gender, tumour localization) and other molecular 
markers (IDH1/2, H3F3A, HIST1H3B, FGFR1, pTERT, BRAF and ATRX). 
The Kaplan Meier survival curve showed a tendency to a worse prognosis in patients 
with translocation of NTRK1 even if the significance threshold is not reached (p-value 
0.095, Figure 10). 
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Figure 10. Kaplan Meier curve. In red, the survival curve of translocated patients 
 
In the following pages, some images of FISH analysis of positive cases are showed. 
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Case number 1 (Figure 11A and B) showed a translocation of NTRK1 in 38% of cells in 
7 high powered fields for a total number of 100 cells.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 A-B.  The red arrows in the images indicate the NTRK1 gene rearrangement in case number 
1. Real magnification: 630X. 
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Case number 2: primary (case 2A) (Figure 12A and B) and recurrent (case 2B) (Figure 
13A and B) tumours demonstrated a concordance in NTRK1 results, showing both a 
translocation in respectively 29% and 20% of cells.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 A-B. The red arrows in the images show the NTRK1 gene rearrangement in case number 
2A, the primary tumour. Real magnification: 1000X. 
 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 A-B.  The red arrows in the images show the NTRK1 gene rearrangement in case the 
recurrent tumour (case 2B). Real magnification: 1000X. 
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 Case number 3 (Figure 13 A-B) reported a gene rearrangement in 25% of cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 A-B. The red arrows in the images indicate the NTRK1 gene rearrangement in case number 
3. Real magnification: 630X. 
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Case number 4 shows 29% of cells translocated for NTRK1 (Figure 14A and B).   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 A-B.  The red arrows in the images show the NTRK1 gene rearrangement in case number 4. 
Real magnification: 630X. 
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Case number 5 reported NTRK1 translocation (figure 15A and B) in 34% of cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 A-B. The red arrows in the images write down the NTRK1 gene rearrangement in case 
number 5. Real magnification: 630X. 
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Case number 6 (Figure 16A and B) displays the gene rearrangement in 17% of cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 A-B. The red arrows in the images show the NTRK1 gene rearrangement in case number 6. 
Real magnification: 630X.
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The other 35 (85%) cases did not show any translocation involving NTRK1 gene. 
 
4.1.2 NTRK2 and NTRK3 status 
Regarding NTRK2 gene we were able to obtain results of 43 (95.5%) cases out of 45. 
Whereas, for NTRK3 gene we reached a result in 42 (93.3%) out of 45 specimens, due 
to the lack of tissue sample.  
Nevertheless, none of the cases reported NTRK2 or NTRK3 gene rearrangements. 
 
4.3 Molecular analysis in circumscribed gliomas76  
 
4.3.1 Clinico-pathological features of pilocytic astrocytomas, gangliogliomas, 
ependymomas and DNET 
We retrospectively identified 108 pilocytic astrocytomas, 80 were from GH Pitié-
Salpêtrière and 28 from AOU Maggiore della Carità. We analysed both the primary and 
the recurrent tumour of 4 patients (posterior fossa (2), supratentorial (1) and optic 
pathway (1)).  
We retrospectively identified 75 grade II and 7 grade III gangliogliomas (all GH Pitié-
Salpêtrière), 100 grade II (81 GH Pitié-Salpêtrière, 19 AOU Maggiore della Carità) and 
26 grade III ependymomas (21 GH Pitié-Salpêtrière, 5 AOU Maggiore della Carità) and 
7 DNETs (all GH Pitié-Salpêtrière). 
The location of the tumours and the main demographic and pathological features are 
reported in Table 6. 
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 PA GG II GG III EP II EP III DNET 
N 108 75 7 100 26 7 
Sex (M/F) 60/48 39/36 2/5 52/48 14/12 3/4 
Mean age at 
surgery in years 
± SD, (range) 
34 ± 15  
(16 – 76) 
34 ± 14  
(15 - 69) 
44 ± 18  
(20 - 65) 
45 ± 16  
(16 – 81) 
40 ± 19  
(16 – 76) 
28 ± 12  
(15 – 48) 
Location, % (n) 
Supratentorial 28.7 
(31/108) 
56 
(42/75) 
42.8 
(3/7) 
11 
(11/100) 
53.9 
(14/26) 
28.6 
(2/7) 
Posterior Fossa 47.2 (51/108) 12 (9/75) 
42.8 
(3/7) 
25 
(25/100) 
26.9 
(7/26) 0 
Optic pathway 8.3 (9/108) 0 0 0 0 0 
Spinal cord 3.7 (4/108) 
1.3 
(1/75) 0 
39 
(39/100) 
19.2 
(5/26) 0 
Not available 12.1 (13/108) 
30.7 
(23/75) 
14.4 
(1/7) 
25 
(25/100) 0 
71.4 
(5/7) 
 
Table 6. Characteristics of the cohort (SD: standard deviation, PA: pilocytic astrocytoma, GG: 
ganglioglioma, EP: ependymoma, DNET: dysembryoplastic neuroepithelial tumour) 
 
4.3.2 FGFR1 activating mutations in circumscribed gliomas 
Activating FGFR1 mutations were identified in 15/108 (13.9%) pilocytic astrocytomas: 
p.Asn546Lys (8 cases), p.Asn546Asp (1 case) and p.Lys656Glu (6 cases) (Table 7). In 
one patient, the p.Asn546Lys mutation was present at progression in the recurrent 
tumour. Strikingly, mutations were more frequent in optic pathway compared to other 
locations (6/9 vs 9/108; p=4.10-5). 
No statistically significant different distribution of sexes (p=0.26) and age (p=0.56) 
were observed between mutated and wild-type pilocytic astrocytomas. 
FGFR1 was mutated in 3/75 grade II vs 2/7 grade III gangliogliomas (p=0.05), 1/7 DNET, 
1/100 ependymoma grade II (Table 8). 
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Location p.Asn546Lys p.Asn546Asp p.Lys656Glu wild-type mut/total (%) 
Supratentorial 2* 0 3 26 5/31 (16.1 %) 
Posterior Fossa 2 0 1 48 3/51 (5.9 %) 
Optic pathway 3 1 2 3 6/9 (66.7 %) 
Spinal cord 0 0 0 4 0/4 (0.0 %) 
Not available 1 0 0 12 1/13 (6.3%) 
*corresponding to the primitive and recurrent tumour of the same patient 
Table 7. FGFR1 mutations’ distribution in pilocytic astrocytoma 
 
 
GG: ganglioglioma, EP: ependymoma, DNET: dysembryoplastic neuroepithelial tumour 
Table 8. BRAF and FGFR1 mutations’ distribution in other circumscribed gliomas 
 
4.3.3 BRAF mutation analysis 
We found 3/108 (2.8%) pilocytic astrocytomas with p.Val600Glu mutation, 6/108 
(5.6%) with p.Thr599_Val600insThr mutation (4/6 cases with c.1797_1798insACA, 2/6 
with c.1796_1797insTAC), 1/108 case with p.Val600_Lys601>Glu 
(c.1799_1801delTGA) (Table 9). In Figure 17A-B-C are reported the electropherograms 
of insertions and deletion detected in BRAF exon 15. 
The p.Val600Glu mutation was found in 14/75 (18.2%) grade II gangliogliomas. The 
p.Val600Glu mutation seems to be associated to a younger age (23 Vs 36 years, 
p=0.0058) but did not show any different distribution between sexes (p=0.88). 
None of ependymomas grade II and III were BRAF mutated (Table 8).  
  
FGFR1 mutations BRAF mutation 
p.Asn546Lys p.Asn546Asp p.Lys656Glu p.Lys656Asn p.Val600Glu 
GG 
grade II 1/75 (1.3%) 0 2/75 (2.6%) 0 14/75 (18.7%) 
GG 
grade III 2/7 (28.6%) 0 0 0 0 
EP grade 
II 1/100 (1%) 0 0 0 0 
EP grade 
III 
0 0 0 0 0 
DNET 0 0 0 1/7 (14.3%) 0 
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In this population we found no p.Thr599_Val600insThr mutation, in contrast to 
pilocytic astrocytomas (6/108 vs 0/215, p=2.10-3) and no p.Val600_Lys601>Glu. 
 
Location p.Val600Glu 
p.Thr599_ 
Val600insThr 
p.Val600_ 
Lys601>Glu 
wild-
type mut/total (%) 
Supratentorial 2 2* 0 27 4/31 (12.9%) 
Posterior 
Fossa 
0 3 (2* + 1**) 0 48 3/51 (5.9%) 
Optic 
pathway 0 0 0 9 0/9 (0%) 
Spinal cord 0 0 0 4 0/4 (0%) 
Not available 1 1** 1 10 3/13 (23%) 
* c.1797_1798insACA - ** c.1796_1797insTAC 
Table 9. BRAF mutations’ distribution in pilocytic astrocytomas 
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Figure 17A-B-C. Electropherograms of BRAF insertions
A B 
C 
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5. DISCUSSION 
 
Gliomas are the most common primary tumours of the central nervous system 
representing 81% of malignant CNS tumours77. According to 2016 World Health 
Organization classification, a specific subgroup of diffuse gliomas arise from midline 
structures which include ventricles, cerebellum, optic pathway/chiasmatic region, 
corpus callosum, hippocampus, hypothalamus, thalamus, pineal gland, brainstem, and 
spinal cord. This subgroup is typically defined by the presence of H3K27M mutation, 
occurring mainly in paediatric age and characterized by a poor prognosis, 
independently to the histological grading but also present in the adult population. 
Moreover, the prognostic impact of H3K27M mutation in adult MLGs differs from 
paediatric gliomas, showing no significant differences with H3K27-WT gliomas78. This 
suggests alternative pathogenic mechanisms between the two groups of MLGs. 
However, the presence of tumours in midline structures is generally associated with a 
poor prognosis also due to technical difficulties for surgical complete resection79. The 
current therapeutical approach for paediatric and adult diffuse gliomas is surgery 
associated with radio and/or chemotherapy, depending on the grade and 
differentiation of the tumour80, but in MLGs since the surgical resection is incomplete 
in most cases, alternative therapeutic strategies are encouraged34,63. 
This retrospective study shows that adult MLG constitute a heterogeneous group with 
mostly high-grade neoplasms and clinical and histomolecular characteristics differing 
from both pediatric MLG and adult supratentorial high-grade gliomas. We identified 
two main subgroups based on the presence of histone H3 or IDH1 mutations, and 
identified hotspot FGFR1 mutations and NTRK1 rearrangements as potential 
therapeutic targets in this population. 
The most prominent molecular subgroup consisted of histone H3 mutant MLG, in line 
with previous studies showing a strong association between histone H3 mutations and 
gliomagenesis of midline tumours2,3,6,9,81. However, we observed a lower prevalence 
of histone H3 mutations compared to pediatric high-grade thalamic and brainstem 
gliomas (70-80%). In addition, clinical and molecular characteristics of patients from 
our cohort with histone H3 mutant MLG differed from pediatric patients. Firstly, 
despite histone H3 mutations were associated with younger age at diagnosis in the 
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French cohort (median 33 years vs. 53 years, p=6*10-5), we found H3 mutation in 
patients over 60 years, indicating that screening for histone H3 mutants should be 
considered in all MLG, regardless of age. Moreover, in contrast to pediatric gliomas, 
we found that histone H3 mutations were not associated with a worse prognosis 
compared to the other IDH wild-type gliomas14.  
The other main driver alteration is IDH mutation, which in the French cohort occurs 
specifically in brainstem (6/24 vs. 0/78 in other midline localizations). The majority of 
IDH1 mutations in this cohort were non-R132H, indicating that the widely used anti-
R132H immunohistochemistry staining is not appropriate in brainstem gliomas and 
have probably underestimated the proportion of IDH1-mutant tumours25. Systematic 
IDH1 sequencing should be performed whenever feasible in brainstem gliomas. Also 
in the Italian cohort we found a rare IDH1 mutation (R132G) among only 4/46 mutated 
cases. Indeed, as observed in hemispheric gliomas, IDH1 mutation is associated with 
better outcome (median survival [MS] = 54.1 versus 15.9 months in French cohort), 
and may in part explain why adults with brainstem gliomas have a better survival than 
children21,25,82. In addition to its prognostic value, the recognition of IDH1 mutations 
may open therapeutic opportunities, as inhibitor of IDH1-mutant enzymes have 
demonstrated antitumour potential and entered clinical trials for patients with IDH1-
mutations23,83,84. 
In addition to IDH1 mutation, we identified here other potentially targetable hotspot 
mutations affecting N546 and K656 residues of FGFR1 in 18% of cases in the French 
cohort and 7% of Italian cohort. FGFR1 mutations were not associated with any 
specific location or any molecular subgroup. Somatic FGFR1 N546 and K656 mutations 
were previously reported in several other cancer types85, comprising a wide range of 
central nervous system (CNS) tumours, including rosette-forming glioneuronal 
tumours86,87, dysembryoplastic neuroepithelial tumours88, pilocytic 
astrocytomas44,89,90, diffuse leptomeningeal tumour with glial and neuronal markers91, 
pediatric thalamic gliomas21,22,92. These studies analysed isolated cases or small 
cohorts, which made difficult the assessment of the incidence of FGFR1 mutations in 
this population. FGFR1 N546 and K656 mutants lead to constitutive activation of 
FGFR1 tyrosine kinase and downstream RAS-MAPK signalling, contributing to 
transformation93-95, and can be targeted by a number of oral inhibitors: notably, the 
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recent clinical development96 of a novel irreversible FGFR inhibitor (e.g. TAS-120) that 
demonstrated potent activity against N550K mutants24,97 open new therapeutic 
opportunities in this population. In our study, we demonstrated that FGFR1 mutations 
are restricted to midline structures because absent in a huge cohort of hemispheric 
gliomas and absent also in public repositories (i.e. Cosmic); these mutations may be 
considered as a hallmark of midline gliomas. 
BRAF V600E is another actionable target, which has been rarely associated with 
H3K27M in pediatric gangliogliomas and diffuse midline gliomas7,98-100. However, the 
French cohort did not show any V600 BRAF mutation in all the 68 sequenced patients 
while in the Italian cohort we found 1 V600E mutated case. 
Our study was restricted by the scarcity of available tumour material limiting both 
histopathological and genomic analyses. Therefore, our genomic analyses were 
restricted to a panel of selected molecular alterations, while several samples were 
exhausted at the time of this retrospective analysis. However, the majority of the 
patients could be assessed for TERT promoter status. As observed in adult 
supratentorial glioblastomas, TERTp mutation, which affected 37% of French cases 
and 35% of Italian cases, was associated with older age, grade IV, poor survival, (also 
with EGFR amplifications and loss of chromosome 10 and deletion of CDKN2A as 
reported in the French cohort). Survival of these patients was particularly poor (OS = 
9.1 months vs. 24.2 months for patients without TERTp mutations in the French cohort 
and 10.5 months vs. 64.2 months in the Italian cohort), even compared to adult 
patients with hemispheric glioblastomas followed in French institution (OS = 13.5 
months)83 which may be related to the inability to resect these tumours. TERT 
promoter appears therefore a biomarker of poor survival in patients with adult MLG. 
In this study, we chose to investigate for rearrangements in NTRK family genes since 
new targeted therapies are available in clinical trials and show encouraging results in 
many tumours harbouring these genetic lesions. NTRKs in normal condition encode 
Trk, a tyrosine kinase receptor, and when activated by the binding of their ligands NGF 
promotes signal transduction involved in proliferation and cell survival61. 
Rearrangements of NTRKs are associated to constitutive activation of Trk that is an 
important driver in tumour development in many human tumours like, colorectal, lung 
and GBMs101. 
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The results of our study indicated a relative high frequency (15%) of NTRK1 
rearrangements, that were randomly distributed in our MLG cohort (Italian), 
independently to the histological grading. Our data are poorly comparable with 
literature, since few authors have evaluated NTRKs rearrangements in adult gliomas 
and, mainly in GBMs reporting a low percentage (1-2.5%) of translocations102. 
Regarding MLGs, there are few studies that have reported NTRKs rearrangements in 
pilocytic astrocytomas and DIPGs in childhood with variables frequencies ranging from 
1% to 4%44,103. 
The main result of our study consisted in demonstrating that NTRK1 rearrangements 
are not sporadic event in this kind of tumours but show a relatively high frequency. 
Since the new therapeutical strategies in several types of solid tumours are addressed 
to the inhibition of specific tyrosin kinase activated receptors, the demonstration of 
the presence of this kind of rearrangements opens the possibility of a new targeted 
therapy also in MLGs. Moreover, our data showed a tendency of worse prognosis in 
cases harbouring NTRK1 rearrangements, even if statistical significance was not 
reached. 
FISH analysis although easy to perform also in routine samples, is not able to identify 
a specific gene partner of fusion and, moreover, is not informative of the function of 
the new chimeric protein. For this reason, FISH can be used as a screening technique, 
but the positive cases need to be additionally evaluated by Next Generation 
Sequencing, in order identify the real function of chimeric protein. 
Since the prognosis of MLGs is unchanged in last decades and therapeutical 
approaches are limited to standard cares, there is an urgent need to explore new 
targetable biomarkers. 
Up to now, the encouraging results seem to come from the discovering that the 
inhibition of TRK-like NTRK1 in MLGs can improve the prognosis and it can be a valid 
alterative for conventional therapeutical strategy. Taken together with FGFR1 
mutations, our results seem to confirm that they can constitute a promising field of 
translational research. 
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MAPK/ERK pathway is involved in the pathogenesis of pilocytic astrocytoma and other 
circumscribed gliomas. In this study we reported the frequency of FGFR1 and BRAF 
activating mutations in a series of 323 adult circumscribed gliomas.  
FGFR1 mutations have been already described in pilocytic astrocytomas44,89,90,104,105. 
Here we found an unexpected high frequency of FGFR1 mutation in optic-pathway 
pilocytic astrocytomas of adults (6/9; p=4.10-5) not affected by Neurofibromatosis 
type-1 (NF1). To the best of our knowledge, this is the first description of the 
association between FGFR1 activating mutations and optic pathway gliomas. This 
finding may be related to the role of FGFR1 signalling in midline commissure 
development106 and the anterior part of the brain107. Interestingly, in diffuse gliomas 
FGFR1 mutations are restricted to midline tumours, as reported in our study75. This 
finding has important practical consequences: as optic pathway PA are hardly 
accessible to surgery, they could be excellent candidates to anti-FGFR therapies. Our 
data suggest that FGFR1 activating mutation may be associated with tumour 
progression in PA as it has been acquired during the transformation of the tumour in 
one patient, and also in gangliogliomas as it is found in 2/7 grade III vs 3/75 grade II 
(p=0.05). 
As expected, we found nearly 20% of BRAF mutation (p.Val600Glu) in ganglioglioma 
independently of the tumour grading. 
In PA, in addition to the p.Val600Glu, we found other BRAF activating mutations. The 
threonine insertion (p.Thr599_Val600insThr) causes an increased kinase activity and 
cellular MEK/ERK activation comparable to those of p.Val600Glu mutation108. 
Strikingly, p.Thr599_Val600insThr mutation was even more frequent than p.Val600Glu 
mutation (6/108 (5.6%) vs 3/108 (2.8%) in PA, while it was absent in the other 
circumscribed gliomas (GG, EP, DNET). The p.Thr599_Val600insThr can be caused by 
two different nucleotide changes: c.1797_1798insACA has never been reported 
before in pilocytic astrocytoma, but only in pleomorphic xanthoastrocytomas55, 
whereas the c.1796_1797insTAC has been reported in pilocytic astrocytomas108,109. 
We also found a three-base pair deletion (c.1799_1801delTGA) leading to the 
substitution of Val600 and Lys601 by a Glu600, which has been reported mostly in 
papillary thyroid carcinomas110, but not in central nervous systems tumours 
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(https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=1133). This deletion 
results in dramatic increase of BRAF kinase activity and increased tumourigenicity109.  
While the BRAF p.Val600Glu mutated tumours are sensitive to anti-BRAF, this is 
unknown for the other BRAF mutations which can be targeted by an anti-MEK, 
inhibiting the downstream effectors. However, taken together these findings provide 
strong opportunities for precision therapies mainly for tumour not easily accessible to 
surgery. 
 
In conclusion, our findings reinforce the need for histological confirmation and 
molecular analyses in adult patients with MLG, given the significant heterogeneity 
among midline tumours and the presence of recurrent potentially targetable 
molecular alterations in these fatal diseases. While IDH1 and TERT promoter 
mutations may assist treatment stratification in adult patients with MLG, we show 
here that histone H3 mutations do not confer worse prognosis in adult patients with 
MLG. Our finding of frequent and potentially targetable FGFR1 mutations and NTRK 
translocation have important clinical implications in the current context of targeted 
therapies, and further reinforces the need for molecular analyses.  
Moreover, even if circumscribed gliomas may not generally represent an aggressive or 
life-threatening disease, in some cases a therapeutical alternative to surgery may be 
the only chance for treatment, especially when the tumour belongs to deep brain 
structures, such as optic pathway. For this reason, molecular analysis of the mutational 
hotspots discussed in this study could be part of the routine procedures. 
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6. FUTURE PERSPECTIVES 
 
We will confirm the presence of NTRK1 rearrangements in FISH-positive MLG also for 
the characterization of the fusion by next generation sequencing (NGS) technique. 
We will extend the NTRK analysis in adult circumscribed gliomas to assess the presence 
and distribution of gene rearrangements. 
We would also expand the cohort of both MLG and circumscribed gliomas in order to 
confirm our data and we would also extend the genetic analysis in other genes 
involved in the MAPK pathway by using NGS gene panels. 
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